Introduction: Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene. A minority of people with CF carry two heterozygous CFTR mutations other than the common Phe508del, complicating diagnosis and treatment. Case Presentation: We report the case of a 25-year-old South American male diagnosed with CF respiratory disease, characterized by a history of recurrent infections, pulmonary Mycobacterium abscessus infection, airway disease on high-resolution CT, and an elevated sweat chloride level (74 mmol/L). Exome sequencing identified a unique combination of CFTR mutations: a pathogenic frameshift variant (c.2052dup) and a variant of unknown clinical significance (c.710A>C). Notably, there were no signs of pancreatic insufficiency. Rectal mucosal organoid cultures demonstrated residual CFTR function with responsiveness to ivacaftor and the combination of elexacaftor, tezacaftor, and ivacaftor. Conclusion: This case highlights a unique combination of heterozygous CFTR variants in a person with CF respiratory disease, which may be amendable to CFTR modulation therapy.

1.
Dörk
T
,
Mekus
F
,
Schmidt
K
,
Boßhammer
J
,
Fislage
R
,
Heuer
T
, et al
.
Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients
.
Hum Genet
.
1994
;
94
(
5
):
533
42
.
2.
Amato
F
,
Bellia
C
,
Cardillo
G
,
Castaldo
G
,
Ciaccio
M
,
Elce
A
, et al
.
Extensive molecular analysis of patients bearing CFTR-related disorders
.
J Mol Diagn
.
2012
;
14
(
1
):
81
9
.
3.
Bobadilla
JL
,
Macek
M
Jr
,
Fine
JP
,
Farrell
PM
.
Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening
.
Hum Mutat
.
2002
;
19
(
6
):
575
606
.
4.
Pérez
MM
,
Luna
MC
,
Pivetta
OH
,
Keyeux
G
.
CFTR gene analysis in Latin American CF patients: heterogeneous origin and distribution of mutations across the continent
.
J Cyst Fibros
.
2007
;
6
(
3
):
194
208
.
5.
Prieto
MD
,
Alam
ME
,
Franciosi
AN
,
Quon
BS
.
Global burden of nontuberculous mycobacteria in the cystic fibrosis population: a systematic review and meta-analysis
.
ERJ Open Res
.
2023
;
9
(
1
):
00336-2022
.
6.
Floto
RA
,
Olivier
KN
,
Saiman
L
,
Daley
CL
,
Herrmann
JL
,
Nick
JA
, et al
.
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
.
Thorax
.
2016
;
71 Suppl 1
(
Suppl 1
):
i1
22
.
7.
Zomer
D
,
van Ingen
J
,
Hofland
R
;
Dutch CF Registry Steering group
.
Epidemiology and management of nontuberculous mycobacterial disease in people with cystic fibrosis, The Netherlands
.
J Cyst Fibros
.
2023
;
22
(
2
):
327
33
.
8.
Hubert
D
,
Fajac
I
,
Bienvenu
T
,
Desmazes-Dufeu
N
,
Ellaffi
M
,
Dall'ava-Santucci
J
, et al
.
Diagnosis of cystic fibrosis in adults with diffuse bronchiectasis
.
J Cyst Fibros
.
2004
;
3
(
3
):
203
22
.
9.
Michl
RK
,
Mentzel
HJ
,
Gerber
A
,
Beck
JF
,
Mainz
JG
.
A patient nicknamed “saline”: atypical course with cystic fibrosis
.
Klin Padiatr
.
2013
;
225
(
5
):
288
9
.
10.
Wiesel
V
,
Aviram
M
,
Mei-Zahav
M
,
Dotan
M
,
Prais
D
,
Cohen-Cymberknoh
M
, et al
.
Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: a multicenter cohort study
.
J Cyst Fibros
.
2024
;
23
(
1
):
41
9
.
You do not currently have access to this content.